X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (46) 46
index medicus (42) 42
humans (40) 40
male (32) 32
female (31) 31
cancer (29) 29
middle aged (28) 28
adult (26) 26
aged (25) 25
tumors (25) 25
sarcoma (24) 24
chemotherapy (22) 22
analysis (15) 15
metastasis (14) 14
aged, 80 and over (13) 13
care and treatment (13) 13
prognosis (13) 13
young adult (13) 13
adolescent (12) 12
hematology, oncology and palliative medicine (11) 11
patients (11) 11
clinical trials (10) 10
disease-free survival (10) 10
surgery (10) 10
treatment outcome (10) 10
apoptosis (9) 9
life sciences (9) 9
research (9) 9
retrospective studies (9) 9
sarcoma - pathology (9) 9
cancer therapies (8) 8
hematology (8) 8
sarcoma - drug therapy (8) 8
antineoplastic agents - therapeutic use (7) 7
diagnosis (7) 7
expression (7) 7
health aspects (7) 7
medical research (7) 7
patient outcomes (7) 7
survival (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
breast-cancer (6) 6
drug therapy (6) 6
medicine & public health (6) 6
mutation (6) 6
phase-ii (6) 6
soft-tissue sarcoma (6) 6
[ sdv.can ] life sciences [q-bio]/cancer (5) 5
activation (5) 5
angiosarcoma (5) 5
child (5) 5
drug administration schedule (5) 5
gene amplification (5) 5
genetic aspects (5) 5
imatinib mesylate (5) 5
metastases (5) 5
pathology (5) 5
research article (5) 5
risk factors (5) 5
solid tumors (5) 5
survival analysis (5) 5
therapy (5) 5
transcription factors - genetics (5) 5
angiogenesis (4) 4
antineoplastic agents (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - adverse effects (4) 4
cancer research (4) 4
cell cycle (4) 4
cell line, tumor (4) 4
cell proliferation - drug effects (4) 4
colorectal cancer (4) 4
combined modality therapy (4) 4
doxorubicin (4) 4
efficacy (4) 4
follow-up studies (4) 4
fusion (4) 4
gastrointestinal stromal tumors - drug therapy (4) 4
imatinib (4) 4
liposarcoma (4) 4
medical colleges (4) 4
medicine, experimental (4) 4
mesh : aged (4) 4
mesh : female (4) 4
mesh : humans (4) 4
mesh : male (4) 4
mesh : middle aged (4) 4
monoclonal antibodies (4) 4
multicenter (4) 4
mutations (4) 4
neoplasm metastasis (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
phase-ii trial (4) 4
piperazines - therapeutic use (4) 4
radiotherapy (4) 4
sarcomas (4) 4
soft-tissue (4) 4
survival rate (4) 4
trabectedin (4) 4
tumor proteins (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 949 - 956
Summary Background Diffuse-type tenosynovial giant cell tumour (dt-GCT) of the soft tissue (alternatively known as pigmented villonodular synovitis), an orphan... 
Hematology, Oncology and Palliative Medicine | PIGMENTED VILLONODULAR SYNOVITIS | DIAGNOSIS | THERAPY | EFFICACY | ONCOLOGY | PERIORBITAL EDEMA SECONDARY | MACROPHAGES | RECEPTOR | ANTIBODY | ARTHRITIS | IMATINIB MESYLATE | Receptor, Macrophage Colony-Stimulating Factor - antagonists & inhibitors | Receptor, Macrophage Colony-Stimulating Factor - immunology | Giant Cell Tumors - immunology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Giant Cell Tumors - pathology | Soft Tissue Neoplasms - drug therapy | Male | Antineoplastic Agents - administration & dosage | Giant Cell Tumors - metabolism | Receptor, Macrophage Colony-Stimulating Factor - metabolism | Synovitis, Pigmented Villonodular - drug therapy | Synovitis, Pigmented Villonodular - pathology | Soft Tissue Neoplasms - immunology | Young Adult | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Drug Administration Schedule | Soft Tissue Neoplasms - metabolism | Synovitis, Pigmented Villonodular - metabolism | Treatment Outcome | Synovitis, Pigmented Villonodular - immunology | Giant Cell Tumors - drug therapy | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Infusions, Intravenous | Monoclonal antibodies | Macrophage colony stimulating factor | Tumors
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 532 - 538
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. 1732 - 1742
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1070 - 1080
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 312 - 319
Journal Article
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 2017, Volume 43, Issue 6, pp. 1117 - 1125
Journal Article
International Journal of Cancer, ISSN 0020-7136, 10/2019, Volume 145, Issue 8, pp. 2135 - 2143
Soft tissue sarcomas (STS) are rare tumors accounting for less than 1% of human cancers. While the highest incidence of sarcomas is observed in elderly, this... 
oncogeriatry | registry | elderly patients | relapse | NETSARC | survival | progression | sarcomas | ONCOLOGY | CANCER | Medical research | Care and treatment | Sarcoma | Analysis | Medicine, Experimental | Metastasis | Pharmaceutical industry | Clinical trials | Survival | Patients | Subgroups | Data bases | Soft tissues | Metastases | Databases | Surgery | Head and neck | Diagnostic systems | Tumors | Geriatrics | Cancer Therapy and Prevention
Journal Article
British Journal of Cancer, ISSN 0007-0920, 2017, Volume 117, Issue 9, pp. 1278 - 1285
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 5/2012, Volume 19, Issue 5, pp. 1551 - 1559
Data regarding the management and outcome of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to 1st-line imatinib and 2nd-line... 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | SURGERY | RESISTANT | ONCOLOGY | KIT | KINASE INHIBITOR | MUTATIONS | SORAFENIB | NILOTINIB | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Multivariate Analysis | Gastrointestinal Neoplasms - genetics | Prognosis | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Gastrointestinal Stromal Tumors - secondary | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Indoles - administration & dosage | Young Adult | Pyrroles - administration & dosage | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Retrospective Studies | Gastrointestinal Stromal Tumors - mortality | Liver Neoplasms - secondary | Gastrointestinal Stromal Tumors - genetics | Gastrointestinal Neoplasms - metabolism | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Risk Factors | Survival Rate | Imatinib Mesylate | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Gastrointestinal Stromal Tumors - drug therapy | Receptor, Platelet-Derived Growth Factor alpha - genetics | Gastrointestinal Stromal Tumors - metabolism | Aged | Benzamides | Mutation | Serum Albumin - metabolism | Antimitotic agents | Medical colleges | Platelet-derived growth factor | Patient outcomes | Analysis | Albumin | Metastasis | Antineoplastic agents | Tumors | Cancer
Journal Article